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Abstract
Introduction: The aim of the current systematic review is to update the pooled survival outcome of patients with T2 glottic
carcinoma treated with either laser surgery (CO2 transoral laser microsurgery [CO2 TOLMS]), radiotherapy (RT), or open
partial laryngectomy (OPL). Methods: A systematic search was performed using the MEDLINE database, Scopus, and Google
scholar. The inclusion criteria were studies of patients with T2N0 glottic tumor, treated with either primary CO2 TOLMS,
definitive curative RT, or primary OPL, and with reported oncological outcome at 5 years calculated with a Kaplan-Meier or Cox
regression method. Results: The results of the current review show that local control (LC) is higher with OPL 94.4%, while there
are no differences in LC at 5-year posttreatment for patients treated with RT, compared to those treated with CO2 TOLMS
(respectively, 75.6% and 75.4%). Primary treatment with OPL and CO2 TOLMS results in higher laryngeal preservation than
primary treatment with RT (respectively 95.8%, 86.9%, and 82.4%).Conclusion: First-line treatment with OPL and CO2 TOLMS
should be encouraged in selected T2 patients, because it results in higher laryngeal preservation and similar LC compared to
primary treatment with RT. The involvement of the anterior commissure in the craniocaudal plane and T2b impaired vocal cord
mobility have a poorer prognosis and LC compared to patients with T2a tumors for both CO2 TOLMS and RT.
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Introduction
Early glottic cancer (Tis-T2) is a highly treatable disease with
excellent survival rates. Many studies examined treatment out-
comes for ‘‘early stage’’ laryngeal cancer, grouping those
treated for carcinoma in situ (Tis), T1a, T1b, and T2 tumors,
but most of the data for early laryngeal cancer are dominated by
T1 and Tis cases.1,2 However, T1 and T2 glottic cancer are
heterogeneous with different growth rates and tendency to
infiltrate, and the therapy achieves different results in terms
of both oncological and functional outcomes.
Available treatment options include CO2 transoral laser
microsurgery (CO2 TOLMS), open partial laryngectomy
(OPL), or radiotherapy (RT). To date, there is no clear evidence
regarding the effectiveness of surgical treatment (CO2 TOLMS
and OPL) over RT, including a recent Cochrane analysis.1-6
The aim of the current systematic review is to compare
single-modality treatments for patients with T2 glottic
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carcinoma through the analysis of survival outcomes, local
control (LC), and laryngeal preservation (LP) in patients
treated with either CO2 TOLMS, RT, or OPL.
Materials and Methods
Search Strategy
Following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines, 2 inde-
pendent researchers conducted a literature search on articles
published as of August 2019 using 3 different databases
(PubMed, Scopus, and Google Scholar) with combinations
of the following terms: laryngeal cancer, early glottic carci-
noma/tumor, laryngeal squamous cell carcinoma, CO2
TOLMS, RT, and OPL on articles published between
January 1990 and August 2019.
Eligibility and Inclusion Criteria
The inclusion criteria were clinical studies in patients with
glottic squamous cell carcinoma staged as a T2N0 according
to the Union for International Cancer Control’s (UICC) TNM
Classification of Malignant Tumours—8th edition7 treated
with either primary CO2 TOLMS, curative RT, or primary
OPL, and with reported oncological outcomes at 5 years cal-
culated with a Kaplan-Meier or Cox regression method. Exclu-
sion criteria were articles not written in English, studies with
less than 10 patients, with concurrent chemoradiotherapy, those
describing surgery combined with adjuvant therapy, and those
describing surgery or RT as salvage therapy.
Data Extraction
Title and abstract of selected papers were carefully read
according to the inclusion and exclusion criteria, and duplicates
were removed. The full text of the included studies was
reviewed with extraction of following data: (1) patient number,
(2) average follow-up time (months), (3) treatment, and (4)
5-year oncological outcome in terms of LC and LP.
Study Quality
The levels of evidence of the included articleswere scored accord-
ing to the standards by Wasserman et al8 as follows: level I: ran-
domized controlled trials, level II: prospective study with internal
control group, level III: retrospective study with internal control
group, level IV: case series without an internal control group, and
level V: consensus or expert opinion without critical appraisal.
Results
Search Results
The results of the search are summarized in Figure. 1. The
initial search identified 3464 studies on MEDLINE database,
Scopus, and Google scholar. Articles published after the 1990s
were selected and imported into a reference management
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram followed in this review. The diagram shows
the information flow through the different phases of the review and illustrates the number of records that were identified and included.
2 Ear, Nose & Throat Journal
software (Endnote, Clarivate Analytics). After the removal of
duplicates, 2258 publications were identified. Papers were
screened in title and abstract, and 249 manuscripts were
reviewed in full text. Sixty-one studies met the inclusion cri-
teria; of these, 38 RT papers, 19 CO2 TOLMS studies, and 4
OPL article provided 5-year oncological outcome data for 1452
patients treated with CO2 TOLMS, 3365 patients treated with
RT, and 366 patients treated with OPL.
Study Characteristics
All 61 included studies were published in peer-reviewed jour-
nals and were case series without an internal control group, a
level IV evidence. No randomized controlled trials studies
were identified.
Oncological Outcomes
Tables 1, 2, 3, and 4 show the oncological results of patients
treated with either CO2 TOLMS, RT, or OPL in the studies
included in this systematic review.The results of theanalysis show
thatweighted averages ofLCwashigherwithOPL (94.4%),while
there were no differences in LC at 5 years for patients treated with
RT, compared to those treated with CO2 TOLMS (respectively,
75.6% and75.4%). Primary treatmentwithOPLandCO2TOLMS
resulted in higher LP in the long term compared to primary treat-
ment with RT (respectively, 95.8%, 86.9%, and 82.4%).
Discussion
The main treatment modalities for early glottic carcinomas
include CO2 TOLMS, RT, and OPL; however, there is no clear
Table 1. Oncological Outcomes of Patient Treated With Radiotherapy.
Author (year) Treatment period Patients Gray Follow-up (months) LC (%) 5 years LP 5 years
Turesson (1991)9 1963-1983 132 46-83 Minimum 48 68.9
Fein (1993)10 1977-1989 115 63-76 Minimum 24 84 84.3%
Stevens (1994)11 1979-1989 31 62 Median 49 70
Klinterberg (1996)12 1969-1991 94 60-72 73
Burke (1997)13 1983-1993 27 50-74 Median 63 70.6
Le (1997)14 1956-1995 83 52-76 Median 116 70
Franchin (1998)15 1985-1996 46 63-68 Median 72 70
Sakata (2000)16 1984-1996 50 64 vs 55-58 (CFX vs AF) Median 69 70.8
Smee (2000)17 1967-1994 116 50-70 Mean 146 72
Haugen (2002)18 1990-1998 45 61-65 Mean 40 88
Garden (2003)19 1970-1998 230 70 Median 82 72
Stoeckli (2003)20 2008-2012 30 68-70.2 Mean 70 67 77
Chen (2003)21 1983-2001 46 63-73 Minimum 12 60 63
Zouhair (2004)22 1983-2000 36 60-74 Median 85 77
Frata (2005)23 1970-1999 256 61-65 Mean 90 73
Murakami (2005)24 1989-1998 27 64-70 Mean 75 61 92
Short (2006)25 1986-1998 43 60-66 vs 55 (CFX vs HFX) Median 59 80.5
Tateya (2006)26 1987-1998 48 60-72 (CFX vs HFX) Mean 80 95.2
Dagan (2007)27 1983-2002 80 63-77 Median 115 82 82
Chera (2010)28 1964-2006 260 74 Median 144 76.5
Jones (2010)29 1987-2006 41 74 Median 70 97.6
Smee (2010)17 1967-2006 142 50-70 Median 91 71.8
Khan (2012)30 1986-2006 54 44-69 Mean 67 75.9
Tong (2012)31 1983-2005 262 57-70 Median 126 79
Al-Mamgani (2013)32 1985-2011 331 66-70 Median 90 78
Douglas (2013)33 1999-2003 128 50-55 Median 71 82
Karasawa (2013)34 2002-2010 24 63 Median 47 67.3
Hoebers (2013)35 2000-2011 120 60 Median 38 78
Higashino (2014)36 2004-2011 20 70 Mean 60 80
Moon (2014)37 2002-2010 16 70 vs 68 (CFX vs HFX) Median 67 56.3-77.8
Rutowski (2014)38 2002-2009 115 45-70 IMRT Minimum 36 72
Motegi (2015)39 1999-2007 44 65 (AF) Minimum 24 77 95
Ermis (2015)40 2004-2013 64 55 (HFX) Median 72 80.9
Lim (2015)41 1981-2010 67 67 Median 85 72
Harada (2015)42 1991-2010 35 74.4 Median 61 86 97
Portenza (2015)43 2000-2010 16 66 Median 75 84
Zumsteg (2015)44 1981-2011 70 60 (CFX vs IMRT) Median 59 75.8
Sert (2019)45 2005-2015 21 65.25 Gy in 29 fractions Median 64 56
Abbreviations: AF, accelerated fractionation; CFX, conventional fractionation; DSS, disease-specific survival; Gy, gray; HFX, hypofractionation; IMRT, Intensity-
modulated radiation therapy; LC, local control; LP, larynx preservation; OS, overall survival.
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evidence regarding the effectiveness of one treatment over the
other.1-4 The results of the current review show that weighted
averages for LC and LP is higher with OPL (94.4% and 95.8%)
compared to CO2 TOLMS (75.4% and 87%) and RT (75.6%
and 82.4).
Our systematic review shows that the number of patients
treated with OPL was lower than that of patients treated with
CO2 TOLMS and RT; this suggests that the role of open sur-
gery for management of laryngeal cancer has gradually
decreased during the past 20 years probably because of the
worse functional outcomes as voice quality and swallowing
results. The development of CO2 TOLMS and improvements
in delivery of RT have replaced the previously standard tech-
niques of OPL for early cancer. In the recent years, CO2
TOLMS has received a great consensus, as the use of CO2
TOLMS as a primary treatment is more cost-effective than
OPL or RT,69-71 and it is usually performed as a day case
procedure. Moreover, a number of optical and molecular exam-
ining technologies have been developed over the last few years
to improve tumor detection and tumor margin identification.
One of the most implemented techniques in clinical practice is
narrow-band imaging (NBI); a significant reduction of positive
superficial margins was found in patients treated with intrao-
perative use of NBI (52%) compared to patients treated without
intraoperative NBI (28.6%; P < .05).72
Laryngeal Preservation
The CO2 transoral laser microsurgery resulted in higher LP
compared to RT; this can be explained by the preservation of
physiological cartilage barriers. Furthermore, laser surgery can
be repeated or followed by other treatment protocols (eg, RT or
OPL) in patients with recurrent disease. Contrarily, both RT
and OPL in primary glottic carcinoma may lead to treatment
limitations in case of recurrence, making organ preservation
Table 2. Oncological Outcomes of Patient Treated With CO2 Transoral Laser Microsurgery.
Author (year) Treatment period Patients Follow-up (months) LC 5 Years (%) LP 5 years (%)
Eckel (2000)46 1987-1996 93 Mean 55 82 93.1
Peretti (2000)47 1987-1994 23 Mean 76 91
Motta (2005)48 1991-1998 236 Mean 60 66 82.5
Peretti (2005)49 1998-2001 55 Mean 58 77 84.8
Rodel (2009)50 1986-2004 102 Median 65 76
Mantsopoulos (2010)51 1977-2004 143 Mean 139 89.4
Peretti (2010)52 1988-2005 109 Mean 84 85.6 95.1
Blanch (2011)53 1998-2008 81 Mean 45.4 40.7 73.2
Lucioni (2011)54 2000-2007 14 Mean 47.9 78.6 100
Canis (2013)55 1979-2006 269 Mean 96 75.8 88.3
Fang (2013)56 2004-2011 30 Median 33 83.3
Lee (2013)57 1997-2011 11 Mean 70 81.8 90
Peretti (2013)58 2005-2010 59 Minimum 18 84
Hoffman (2015)59 2001-2013 19 Mean 44 63.6 90.9
Ansarin (2017)60 1999-2013 90 Median 72 91.1
Day (2017)61 1995-2011 17 Median 44.6 86 88
Chang (2017)62 2003-2009 20 Medium 35 84
Carta (2018)63 1993-2005, 2010-2016 41 Median 52 79,5 88
Pedregal-Mallo (2018)64 1998-2013 40 Minimum 24 70
Abbreviations: CO2 TOLMS, transoral CO2 laser microsurgery; LC, local control; LP, larynx preservation.
Table 3. Oncological Outcomes of Patient Treated With OPL.
Author (year) Treatment period Patients Follow-up (months) LC 5 years (%) LP 5 years
Succo (2016)65 1995-2011 207 63 97.5% 98%
Giovanni (2001)66 1982-1997 65 92% 92%
Camprette (1998)67 1984-1993 23 Minimum 15 83%
Spector (1999)68 1971-1989 71 Minimum 60s 93% 93%
Abbreviations: LC, local control; LP, laryngeal preservation; OPL, open partial laryngectomy.
Table 4. Weighted Averages of the Oncological Outcomes for CO2
TOLMS, RT, or OPL.
Treatment Patients LC 5 years (%) Patients LP 5 years (%)
CO2 TOLMS 1362 75.4 1094 87
RT 3365 75.63 346 82.4
OPL 366 94.40 343 95.8
Abbreviations: CO2 TOLMS, transoral CO2 laser microsurgery; LC, local con-
trol; LP, larynx preservation; OPL, open partial laryngectomy; RT,
radiotherapy.
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more unlikely. In addition, patients undergoing salvage surgery
post-RT have a greater number of complications than patients
post-CO2 TOLMS. Overall complication rate in salvage sur-
gery post-RT ranges from 5% to 78% with the most common
complication being pharyngocutaneous fistula formation
occurring in as many as 73% of cases in the salvage setting.73,74
Local Control
Evidence confirms that patients with T2b and vocal cord mobi-
lity have a poorer prognosis and LC compared to patients with
T2a tumors for both CO2 TOLMS
3,55 and RT9,10,13,27,28,30,75,76
while data on OPL are not enough to evaluate the oncological
outcomes in these patients. In a recent case series, Succo et al65
affirmed that OPL is safer in case of T2b compared to CO2
TOLMS; however, it led to more dysfunctional sequelae. The
authors concluded that OPL should be performed in selected
patients affected by glottic cT2 with impaired mobility of vocal
cords and suspected extension to the paraglottic space (PGS).
Rucci et al77 observed that the dorsal compartment of the glot-
tic site is in close proximity to the paraglottic space. The inter-
nal cricoarytenoid ligaments oppose for a short length of time
to the penetration of early glottic cancer into the paraglottic
space toward the cricoarytenoid joints. Lesions invading the
paraglottic space should be correctly classified as T3 during
the preoperative evaluation with a transnasal flexible videofi-
berscope and magnetic resonance imaging.78 Poorer prognosis
seems to be associated mainly with tumor infiltration of the
posterior paraglottic space resulting in fixation of the arytenoid
joint and not with impaired mobility from vocal fold muscle
infiltration or pure tumor bulk.6
Involvement of the Anterior Commissure
The treatment of the T2 glottic cancer with involvement of
anterior commissure (AC) is also controversial. Laccourreye
et al79 found that among 416 patients with T1 or T2 laryngeal
cancers undergoing vertical partial laryngectomies, the failure
rate was 23% if the AC was involved; higher than at other
anatomic subsites. Studies on CO2 TOLMS
52-54,58,59,63 and
studies on RT20,21,24,25,76 analyzed the involvement of the
AC and concluded that its involvement did not result in a
significantly lower overall survival rate. However, Hoffmann
et al (96 patients) and Carta et al (105 patients), in large
sample-sized studies, revealed a significantly increased risk for
local recurrences in patients with extensive infiltration of the
AC.59,63,80
The vertical plane of the AC has been identified as a lar-
yngeal subsite at risk for local treatment failures.81-84 In the
ventral compartment, cancer can easily diffuse superficially
along the ventral mucosa containing blood vessels and glands;
this diffusion usually follows a cranial-to-caudal direction.
Moreover, if cancer reaches in depth the Broyles tendon, it can
invade adjacent structures. Therefore, an early-stage carcinoma
with involvement of the AC could penetrate the cartilage trans-
forming a T1 tumor into a T4 switch, thus representing a
contraindication for CO2 TOLMS. The impact of the AC invol-
vement on prognosis in laryngeal cancer remains a topic with
inconsistent results in the literature; a detailed stratification of
tumors involving the AC needs to be investigated in further
studies for all treatment modalities.85
Limits of the Study
The main limitation of this review is the vast heterogeneity of
selected studies. Radiotherapy studies have a large variety in
technique, fraction size, and overall dose, while CO2 TOLMS
studies did not describe which resections were performed dur-
ing surgery. Furthermore, there are no randomized trials or
comparison studies; all the selected studies are retrospective
case series. For this reason, formal statistical analysis and
meta-analysis are inappropriate. It is very important to under-
line that in the majority of studies on CO2 TOLMS, there was
some selection of patients. Large T2 tumor or tumor with the
involvement of AC may not be suitable for a transoral
approach, and treatment must be individualized according to
patient anatomy. Finally, there was heterogeneity in treatment
details, treatment period, study design, and follow-up for both
treatment modalities.
Conclusions
The current first-line treatments for early laryngeal cancer are
CO2 TOLMS and RT, while the role of OPL has greatly dimin-
ished in the last 20 years. This review suggests that CO2
TOLMS should be encouraged in selected T2 patients, because
LC is comparable but primary treatment with CO2 TOLMS
results in higher LP compared to primary treatment with RT.
In conclusion, data suggest that involvement of the AC in the
craniocaudal plane and T2b impaired vocal cord mobility have
a poorer prognosis and LC compared to patients with T2a
tumors for both CO2 TOLMS and RT. Open partial laryngect-
omy should be proposed in selected patients affected by glottic
cT2 with impaired mobility of vocal cords and suspected exten-
sion to the PGS. Further studies on cancers with the involve-
ment of AC and impaired vocal cord are necessary to clarify
their impact on oncological outcomes, and prospective rando-
mized controlled studies for both treatment modality are
required to confirm these results.
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